Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update

Authors :: Michele Aieta
Francesca Pucci
Giusi Blanco
Sara Pusceddu
Emilio Bajetta
Italo Sarno
Nicola Fazio
S. Ricci
Lorenzo Dottorini
Francesca Spada
G. Di Menna
Laura Catena
Source :: Annals of Oncology. 26:vi132
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
Everolimus
business.industry
First line
Hematology
Neuroendocrine tumors
Pharmacology
medicine.disease
Octreotide lar
Internal medicine
medicine
business
medicine.drug

Full Text Access

Tools